Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Greenwich Lifesciences Inc A Clinical-Stage Biopharmaceutical Company Focused On Its Phase Iii Clinical Trial, Flamingo-01, Which Is Evaluating Glsi-100, An Immunotherapy To Prevent Breast Cancer Recurrences. Gp2 Is A 9-Amino-Acid Transmembrane Peptide Of The Her2/Neu Protein, A Cell Surface Receptor Protein That Is Expressed In A Variety Of Common Cancers, Including Breast Cancers At Low (1+), Intermediate (2+), And High (3+ Or Overexpressing) Levels.